Other
Urgency Urinary Incontinence
10
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Urgency Urinary Incontinence is an early-stage landscape with 10 programs across 3 companies. The most active players are Astellas, Vitae Pharmaceuticals Inc., an Allergan affiliate, Revance Therapeutics, Inc.. 7 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Analysis
Trial Status
7
clinical trials
Completed5 · 71%
Active, not recruiting2 · 29%
Clinical Trials
Trial Activity
7 trials
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Active, not recruiting·WWomen and Infants Hospital of Rhode Island·Approved·NCT05806164·432 enrolled
A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence
Completed·—·Phase 4·NCT01505439·311 enrolled
Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Completed·—·Phase 4·NCT04090190·20 enrolled
Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
Completed·—·Phase 4·NCT04227184·207 enrolled
Effect of Diaphragmatic Training on Urgency Urinary Incontinence in Postmenopausal Women
Completed·—·N/A·NCT06521008·60 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)